Transaction DateRecipientSharesTypePriceValue
31st December 2020John W. Higuchi1,700Open or private sale$1.35$2,286.50
31st December 2020John W. Higuchi5,000Open or private sale$1.35$6,767.00
16th December 2020Jeffrey Arvin Fink5,625Exercise of derivative$0.00
16th December 2020Mahesh V. Patel15,000Open or private sale$1.35$20,250.00
16th December 2020Mahesh V. Patel45,000Exercise of derivative$0.00
16th December 2020John W. Higuchi3,750Exercise of derivative$0.00
16th December 2020Morgan R Brown8,437Open or private sale$1.35$11,389.95
16th December 2020Morgan R Brown28,125Exercise of derivative$0.00
16th December 2020Richard Dana Ono5,250Exercise of derivative$0.00
16th December 2020Stephen A Hill7,500Exercise of derivative$0.00
Lipocine logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Lipocine, Inc. focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Ticker: LPCN
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1535955
Employees: 12
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags